Showing 1 - 5 results of 5 for search 'Shringi Sharma', query time: 0.03s Refine Results
  1. 1
    Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia

    Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia by Florencia A. Tettamanti, Holly Kimko, Shringi Sharma, Giovanni Di Veroli

    Published 2024-08-01
    Get full text
    Article
  2. 2
    Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

    Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia by Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, William Townsend, Amanda G. Paulovich, Jeffrey R. Whiteaker, Fanny Krantz, Chuan-Chuan Wun, Graeme Parr, Shringi Sharma, Veerendra Munugalavadla, Richa Manwani, Emma Dean, Talha Munir

    Published 2023-05-01
    Get full text
    Article
  3. 3
    P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANALYSIS

    P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANA... by Jake Shortt, Tatyana Feldman, Graham Collins, Jasmine Zain, Amit Khot, Jin Seok Kim, Franck Morschhauser, Tae Min Kim, Justine Roderick, Jeong Lim Yoon, Shringi Sharma, Jamal Saeh, Jiale Dai, Ruben Reyes, Richardp Olsson, Pier Luigi Zinzani

    Published 2023-08-01
    Get full text
    Article
  4. 4
    P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

    P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY by Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, James S. Blachly, Ian W. Flinn, Susan O’brien, Jacqueline Garcia, Neha Korde, Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Jamal Saeh, Raoul Tibes, Marcio Andrade, Tapan Kadia

    Published 2023-08-01
    Get full text
    Article
  5. 5
    P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

    P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL by Giovanni Marconi, Shukaib Arslan, Shaun Fleming, Antonio Curti, James S Blachly, Giovanni Martinelli, Matteo Giovanni Della Porta, Ashish Bajel, Tim Sauer, Martina Crysandt, Arnaud Pigneux, Marina Konopleva, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Emily Rowe, Patricia Cheung, Ekaterina Jahn, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Nitin Jain

    Published 2023-08-01
    Get full text
    Article

Search Tools: